To include your compound in the COVID-19 Resource Center, submit it here.

Vismodegib: Additional Phase II data

Additional data from the open-label, single-arm, international, pivotal Phase II ERIVANCE BCC trial in 104 patients with inoperable advanced BCC showed that once-daily 150 mg oral vismodegib produced an ORR of 43% in patients with locally advanced BCC (laBCC; n=71) and 30% in patients with metastatic BCC (mBCC; n=33) as assessed by independent review, which was

Read the full 565 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE